Virbac

VIRP

FR0000031577

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:37:42 2025-06-20 am EDT			5-day change	1st Jan Change
323.50 ^EUR	+0.15%		+1.73%	+2.21%

Jun. 19	Virbac SA Appoints Paul Martingell as Chief Executive Officer, Effective September 1, 2025	CI
Jun. 19	France's Virbac Names New CEO	MT

Virbac SA acquired Mopsan Veteriner Urunleri A.S.

Published on 12/02/2024 at 18:00

Virbac SA (ENXTPA:VIRP) acquired Mopsan Veteriner Urunleri A.S. on December 2, 2024.
Virbac SA (ENXTPA:VIRP) completed the acquisition of Mopsan Veteriner Urunleri A.S. on December 2, 2024.

Latest news about Virbac

Virbac SA Appoints Paul Martingell as Chief Executive Officer, Effective September 1, 2025	Jun. 19	CI
France's Virbac Names New CEO	Jun. 19	MT
Virbac: new CEO from early September	Jun. 19	CF
Virbac To Appoint Paul Martingell As CEO	Jun. 19	RE
VIRBAC : Decent Q1; Clarity on US tariff exposure was a key takeaway	Apr. 16
VIRBAC : Stifel still buying after Q1 results	Apr. 16	CF
French and Benelux stocks-Factors to watch	Apr. 16	RE
Virbac: Q1 sales up 8.5%	Apr. 15	CF
Virbac Q1 Revenue EUR 375.2 Million	Apr. 15	RE
Virbac Q1 2025 Revenue EUR 375.2 Mln	Apr. 15	RE
Virbac: surrounded on the back of a broker upgrade	Mar. 17	CF
VIRBAC : Oddo BHF remains 'neutral', confirms its target	Mar. 17	CF
VIRBAC : 2024 profitability somewhat exceeded expectations; stock re-rating underway	Mar. 17
VIRBAC : Stifel raises its recommendation	Mar. 17	CF
Virbac SA Seeks Acquisitions	Mar. 14	CI
Virbac SA, 2024 Earnings Call, Mar 14, 2025	Mar. 14
French and Benelux stocks-Factors to watch	Mar. 14	RE
Virbac: 20% increase in consolidated net income by 2024	Mar. 13	CF
Virbac SA Provides Financial Guidance for the Fiscal 2025	Mar. 13	CI
Virbac SA Reports Earnings Results for the Full Year Ended December 31, 2024	Mar. 12	CI
VIRBAC : 2024 top-line goals met; uninspiring 2025 outlook could be raised later	Jan. 17
Oddo BHF Downgrades Virbac to Neutral, Cuts PT	Jan. 17	MT
Virbac forecasts sales growth of 4 to 6% in 2025	Jan. 16	RE
Virbac SA Provides Revenue Guidance for the Year 2025	Jan. 16	CI
Virbac SA Reports Non-Audited Consolidated Revenue Results for the Fourth Quarter and Full Year Ended December 2024	Jan. 16	CI

Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (61.6%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (38.4%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (40.8%), Latin America (15.9%), North America (13%), India/Africa/Middle East (12.5%), East Asia (10.1%) and Pacific (7.7%).

Employees

6,365

Sector

Pharmaceuticals

Calendar

Jun. 23 - Détachement de for final dividend

More about the company